Amabel C L Tan
Overview
Explore the profile of Amabel C L Tan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
263
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zeng W, Horrocks K, Tan A, Wong C, Chua B, Jackson D
Vaccine
. 2019 Nov;
38(3):597-607.
PMID: 31740096
To facilitate the preparation of synthetic epitope-based self-adjuvanting vaccines capable of eliciting antibody responses in an out-bred population, we have developed two modular approaches. In the first, the Toll-like receptor...
2.
Chua B, Wong C, Mifsud E, Edenborough K, Sekiya T, Tan A, et al.
mBio
. 2015 Oct;
6(6):e01024-15.
PMID: 26507227
Unlabelled: The continual threat to global health posed by influenza has led to increased efforts to improve the effectiveness of influenza vaccines for use in epidemics and pandemics. We show...
3.
Mifsud E, Tan A, Reading P, Jackson D
Immunol Cell Biol
. 2015 Aug;
94(2):169-76.
PMID: 26272554
We have previously shown that intranasal administration of the Toll-like receptor-2 agonist, S-(2,3-bis(palmitoyloxy)propyl) cysteine (Pam2Cys), provides immediate and antigen independent protection against challenge with influenza virus. Here we characterize the...
4.
Mifsud E, Tan A, Brown L, Chua B, Jackson D
Front Immunol
. 2015 Jun;
6:290.
PMID: 26097481
Immunostimulatory agents provide a new category of anti-microbial agents that activate the host's innate immune system allowing control of viral and/or bacterial infections. The TLR-2 agonist PEG-Pam2Cys has been shown...
5.
Zeng W, Tan A, Horrocks K, Jackson D
Vaccine
. 2015 Jun;
33(30):3526-32.
PMID: 26049002
The highly conserved extracellular domain of Matrix protein 2 (M2e) of influenza A virus has been previously investigated as a potential target for an universal influenza vaccine. In this study...
6.
Mifsud E, Tan A, Jackson D
Front Immunol
. 2014 Mar;
5:79.
PMID: 24624130
Immunotherapies that can either activate or suppress innate immune responses are being investigated as treatments against infectious diseases and the pathology they can cause. The objective of these therapies is...
7.
Tan A, Deliyannis G, Bharadwaj M, Brown L, Zeng W, Jackson D
Immunol Cell Biol
. 2012 Nov;
91(1):96-104.
PMID: 23146941
In this study, we examined the reactivity of human peripheral blood mononuclear cells to a panel of influenza A virus (IAV) CD8(+) T-cell epitopes that are recognised by the major...
8.
Tan A, Mifsud E, Zeng W, Edenborough K, McVernon J, Brown L, et al.
Mol Pharm
. 2012 Jul;
9(9):2710-8.
PMID: 22823162
The protective role played by the innate immune system during early stages of infection suggests that compounds which stimulate innate responses could be used as antimicrobial or antiviral agents. In...
9.
Tan A, Eriksson E, Kedzierska K, Deliyannis G, Valkenburg S, Zeng W, et al.
Antiviral Res
. 2012 Apr;
94(2):168-78.
PMID: 22504097
In hepatitis C virus (HCV) infection, CD8(+) T cell responses have been shown to be important in viral clearance. Examining the efficacy of CD8(+) T cell vaccines against HCV has...
10.
Tan A, La Gruta N, Zeng W, Jackson D
J Immunol
. 2011 Jul;
187(4):1895-902.
PMID: 21765016
The human HLA-A2-restricted CD8(+) T cell response to influenza A virus (IAV) is largely directed against the matrix protein-derived M1(58-66) epitope and represents an archetypal example of CD8(+) T cell...